ARTICLE
26 July 2019

Novel Pyrrolo[3,2-D]Pyrimidine Compounds Target Mitochondrial And Cytosolic One-Carbon Metabolism With Broad-Spectrum Antitumor Efficacy

KL
Herbert Smith Freehills Kramer LLP

Contributor

Herbert Smith Freehills Kramer is a world-leading global law firm, where our ambition is to help you achieve your goals. Exceptional client service and the pursuit of excellence are at our core. We invest in and care about our client relationships, which is why so many are longstanding. We enjoy breaking new ground, as we have for over 170 years. As a fully integrated transatlantic and transpacific firm, we are where you need us to be. Our footprint is extensive and committed across the world’s largest markets, key financial centres and major growth hubs. At our best tackling complexity and navigating change, we work alongside you on demanding litigation, exacting regulatory work and complex public and private market transactions. We are recognised as leading in these areas. We are immersed in the sectors and challenges that impact you. We are recognised as standing apart in energy, infrastructure and resources. And we’re focused on areas of growth that affect every business across the world.
Intellectual Property scientific advisor Khushbu Shah co-authored an article titled "Novel Pyrrolo[3,2-d]Pyrimidine Compounds Target Mitochondrial and Cytosolic One-Carbon Metabolism
United States Food, Drugs, Healthcare, Life Sciences

Intellectual Property scientific advisor Khushbu Shah co-authored an article titled “Novel Pyrrolo[3,2-d]Pyrimidine Compounds Target Mitochondrial and Cytosolic One-Carbon Metabolism with Broad-Spectrum Antitumor Efficacy” which was published in AACR Journals on July 9, 2019. The article describes structure-activity relationships and identifies exciting new drug prototypes for development as multi-targeted antitumor agents.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More